Wonder Sir Founder on the State of Rare Disease Patient Organizations in China
This is the last part of my conversation with Wonder Sir founder Chen Yiwei. You can find our interview'
NHSA Insurance Funding Expert Zheng Jie: Shifting from Excessive Price Reduction to Value-Based Procurement for China's Drug Pricing Dilemma
At the 5th China Rare Disease Cooperation and Exchange Conference, Zheng Jie, the leader of the Insurance Funding Analysis Expert
Wonder Sir Founder on Pharma Success: The Importance of Early Investment and Trust in China
“In my capacity as a researcher, I've had experience in both scientific research and drug development. Additionally, as
Wonder Sir Founder Chen Yiwei on China’s Rare Disease Definition and Recent Policy Boost for Foreign CGT Investment
Motivated by a profound sense of purpose and deeply moved by the suffering of Chinese rare disease patients, Chen Yiwei,
Improving Access to Innovative Drugs: Can China’s Dual-Channel Policy Deliver?
To tackle the hospital formulary access issues faced by some NRDL-negotiated drugs, the National Healthcare Security Administration (NHSA) introduced the
Shanghai Enhances Payment Mechanisms to Drive Pharma and Medical Innovation
Shortly after the National Healthcare Security Administration (NHSA) introduced its more industry-friendly renewal rules for older NRDL-negotiated drugs, the Shanghai
China Implements More Moderate and Predictable Price Reduction for Older NRDL-Negotiated Drugs
In late June, the National Healthcare Security Administration (NHSA) commenced the 2023 National Reimbursement Drug List (NRDL) Dynamic Update, aiming
Chinese Organization for Rare Disorders Founder Kevin Huang: China is Focusing on Solving Orphan Drug Access Issues
On a beautiful Wednesday morning, just after celebrating July 4th, I sat down with Kevin Huang, the visionary founder of
Behind the Scenes: Exploring the Roadblocks to Formulary Listing for NRDL-Negotiated Drugs in China Public Hospitals
China's National Reimbursement Drug List (NRDL) is increasingly incorporating innovative drugs. Once included in the NRDL, these drugs
Navigating China's Access Landscape for Orphan Therapies: Insights into Funding Pathways
Welcome back to the final installment of our three-part series exploring China's access landscape of rare disease therapies.
